In vivo evaluation of curcumin loaded nanosuspensions by oral administration

Journal of Biomedical Nanotechnology

Volumn 8, Issue 4, 2012, Pages 659-668

  Gao, Yan ^a   Wang, Chao ^a   Sun, Min ^b   Wang, Xin ^c   Yu, Aihua ^a   Li, Aiguo ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b Central Hospital of Zibo   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Bioavailability; Curcumin; Nanosuspension; Oral absorption

Indexed keywords

ABSORPTION PROCESS; AFTER-TREATMENT; AVERAGE DIAMETER; BIOAVAILABILITY; CONCENTRATION-TIME; CURCUMIN; FLUORESCENCE POLARIZATION; GASTROINTESTINAL TRACT; HIGH PRESSURE HOMOGENIZATION; IN-SITU; IN-VITRO; IN-VIVO; MEMBRANE PROTEINS; NANO-SUSPENSIONS; ORAL ABSORPTION; ORAL ADMINISTRATION; ORAL DELIVERY; PASSIVE DIFFUSIONS; PHARMACOKINETIC STUDIES; RELATIVE BIOAVAILABILITY; SINGLE PASS; SPHERICAL SHAPE;

BIOCHEMISTRY; BIOLOGICAL MEMBRANES; RATS; TRANSMISSION ELECTRON MICROSCOPY;

SUSPENSIONS (FLUIDS);

CURCUMIN; NANOPARTICLE; NANOSUSPENSION; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BETA SHEET; CIRCULAR DICHROISM; COLON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SOLUBILITY; DUODENUM; ILEUM; INTESTINE ABSORPTION; INTESTINE MUCOSA; JEJUNUM; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CURCUMIN; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINES; MALE; MICE; NANOSPHERES; RATS; RATS, WISTAR; STOMACH;

EID: 84865124294     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1425     Document Type: Article

References (64)

1. R. K. Maheshwari, A. K. Singh, J. Gaddipati, and R. C. Srimal, Multiple biological activities of curcumin: A short review. Life Sci. 78, 2081 (2006).
2. S. Shishodia, M. M. Chaturvedi, and B. B. Aggarwal, Role of curcumin in cancer therapy. Curr. Probl. Cancer 31, 243 (2007).
3. Q. Y. Wei, W. F. Chen, B. Zhou, L. Yang, and Z. L. Liu, Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim. Biophys. Acta 1760, 70 (2006).
4. S. K. Jain, J. Rains, and K. Jones, Effect of curcumin on protein glycosylation, lipid peroxidation, and oxygen radical generation in human red blood cells exposed to high glucose levels. Free Radic. Biol. Med. 41, 92 (2006).
5. N. S. Rejinold, M. Muthunarayanan, K. P. Chennazhi, S. V. Nair, and R. Jayakumar, Curcumin loaded fibrinogen nanoparticles for cancer drug delivery. J. Biomed. Nanotechnol. 7, 521 (2011).
6. A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu, Y. F. Ho, T. S. Shen, J. Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, H. S. Yu, S. H. Jee, G. S. Chen, T. M. Chen, C. A. Chen, M. K. Lai, Y. S. Pu, M. H. Pan, Y. J. Wang, C. C. Tsai, and C. Y. Hsieh, Phase I clinical trial of curcumin, chemo-preventive agent, in patients with highrisk or pre-malignant lesions. Anticancer Res. 21, 2895 (2001).
7. S. K. Kurd, N. Smith, A. VanVoorhees, A. B. Troxel, V. Badmaev, J. T. Seykora, and J. M. Gelfand, Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J. Am. Acad Dermatol. 58, 625 (2008).
8. R. Kuttan, P. C. Sudheeran, and C. D. Josph, Turmeric and curcumin as topical agents in cancer therapy. Tumori. 73, 29 (1987).
9. R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, M. Pirmohamed, A. J. Gescher, and W. P. Steward, Phase I clinical trial of oral curcumin: biomar-kers of systemic activity and compliance. Clin. Cancer Res. 10, 6847 (2004).
10. M. Singh and N. Singh, Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol. Cell Biochem. 325, 107 (2009).
11. P. Anand, A. B. Kunnumakkara, R. A. Newman, and B. B. Aggarwal, Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807 (2007).
12. C. D. Lao, M. T. Ruffin, D. Normolle, D. D. Heath, S. I. Murray, J. M. Bailey, M. E. Boggs, J. Crowell, C. L. Rock, and D. E. Brenner, Dose escalation of a curcuminoid formulation. BMC Complement Altern. Med. 6, 10 (2006).
13. S. Bisht, G. Feldmann, S. Soni, R. Ravi, C. Karikar, and A. Maitra, Polymeric nanoparticles encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J. Nanobiotechnol. 5, 3 (2007).
14. J. Cui, B. Yu, Y. Zhao, W. W. Zhu, H. L. Li, H. X. Lou, and G. X. Zhai, Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int. J. Pharm. 371, 148 (2009).
15. S. Ganta and M. Amiji, Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 6, 928 (2009).
16. M. O. Iwunze, Binding and distribution characteristics of curcumin solubilized in CTAB micelle. Mol. Liq. 11, 161 (2004).
17. L. Li, F. S. Braiteh, and R. Kurzrock, Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104, 1322 (2005).
18. K. Maiti, K. Mukherjee, A. Gantait, B. P. Saha, and P. K. Mukherjee, Curcumin- phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 330, 155 (2007).
19. A. Paradkar, A. A. Ambike, B. K. Jadhav, and K. R. Mahadik, Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int. J. Pharm. 271, 281 (2004).
20. K. Sou, S. Inenaga, S. Takeoka, and E. Tsuchida, Loading of curcumin into macrophages using lipid-based nanoparticles. Int. J. Pharm. 352, 287 (2008).
21. K. Maiti, K. Mukherjee, A. Gantait, B. P. Saha, and P. K. Mukherjee, Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 330, 155 (2007).
22. K. Sou, S. Inenaga, S. Takeoka, and E. Tsuchida, Loading of curcumin into macrophages using lipid-based nanoparticles. Int. J. Pharm. 352, 287 (2008).
23. C. M. Keck and R. H. Müller, Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 62, 3 (2006).
24. A. Schroeter, T. Engelbrecht, R. H. Neubert, and A. S. Goebel, New nanosized technologies for dermal and transdermal drug delivery. A review. J. Biomed. Nanotechnol. 6, 511 (2010).
25. G. G. Liversidge and K. C. Cundy, Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125, 91 (1995).
26. P. K. Mittapalli, M. R. Yamasani, and A. Shashank, Formulation of nanosuspensions of albendazole for oral administration. Current Nanoscience 4, 53 (2008).
27. L. Gao, D. R. Zhang, and M. H. Chen, Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 10, 845 (2008).
28. R. H. Müller, C. Jacobs, and O. Kayser, Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3 (2001).
29. D. R. Zhang, T. W. Tan, L. Gao, W. Zhao, and P. Wang, Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev. Ind. Pharm. 33, 569 (2007).
30. Y. F. Ho, M. Y. Lai, H. Y. Yu, D. K. Huang, W. C. Hsueh, T. H. Tsai, and C. C. Lin, Application of rat in situ single-pass intestinal perfusion in the evaluation of presystemic extraction of indinavir under different perfusion rates. J. Formos. Med. Assoc. 107, 37 (2008).
31. N. N. Song, Q. S. Li, and C. X. Liu, Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J. Gastroenterol. 12, 4064 (2006).
32. Y. Chen, G. Li, X. G. Wu, Z. Y. Chen, J. G. Hang, B. Qin, S. Chen, and R. H. Wang, Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. Biol. Pharm. Bull. 31, 118 (2008).
33. J. Shaikh, D. D. Ankola, V. Beniwal, D. Singh, and M. N. V. R. Kumar, Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 37, 223 (2009).
34. P. Z. Milani, H. Valizadeh, H. Tajerzadeh, Y. Azarmi, Z. Islambolchilar, S. Barzegar, and M. Barzegar-Jalali, Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J. Pharm. Pharmaceut. Sci. 10, 368 (2007).
35. S. Berggren, J. Hoogstraate, U. Fagerholm, and H. Lennernäs, Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. Eur. J. Pharm. Sci. 21, 553 (2004).
36. Y. Q. Hu, L. Y. Zheng, C. Q. Qian, and W. H. Yu, Absorption of phenol red from rat intestine. J. Chin. Pharm. Univ. 27, 355 (1996).
37. Y. Masaoka, Y. Tanaka, M. Kataoka, S. Sakuma, and S. Yamashita, Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur. J. Pharm. Sci. 29, 240 (2006).
38. H. L. Li, X. B. Zhao, Y. K. Ma, G. X. Zhai, L. B. Li, and H. X. Lou, Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control. Release. 133, 238 (2009).
39. Y. Pak, R. Patek, and M. Mayersohn, Sensitive and rapid iso-cratic liquid chromatography method for the quantitation of curcumin in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796, 339 (2003).
40. P. Liu, S. Liang, B. J. Wang, and R. C. Guo, Pharmacokinetics, safety and tolerance of single- and multiple-dose of a novel compound tramadol hydrochloride injection (35mg tramadol hydrochloride, 45mg promethazine hydrochloride) in Chinese healthy subjects. Eur. J. Drug Metab. Pharmacokinet. 34, 193 (2009).
41. Z. Ma, A. Shayeganpour, D. R. Brocks, A. Lavasanifar, and J. Samuel, High-performance liquid chromatography analysis of curcumin in rat plasma: Application to pharmacokinetics of polymeric micellar formation of curcumin. Biomed. Chromatogr. 21, 546 (2007).
42. C. Y. Cui, W. L. Lu, S. Q. Zhang, Y. B. Huang, S. L. Li, R. J. Zhang, G. L. Wang, X. Zhang, and Q. Zhang, Sublingual delivery of insulin: effects of enhancers on the mucosal lipid fluidity and protein conformation, transport, and in vivo hypoglycemic activity. Biol. Pharm. Bull. 28, 2279 (2005).
43. H. Boudad, P. Legrand, G. Lebas, M. Cheron, D. Duchêne, and G. Ponchel, Combined hydroxypropyl-beta-cyclodex-trin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int. J. Pharm. 218, 113 (2001).
44. Y. Gao, Z. Li, M. Sun, H. Li, C. Guo, J. Cui, A. Li, F. Cao, Y. Xi, H. Lou, and G. X. Zhai, Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev. Ind. Pharm. 36, 1225 (2010).
45. B. A. Graf, C. Ameho, G. G. Dolnikowski, P. E. Milbury, C. Y. Chen, and J. B. Blumberg, Rat gastrointestinal tissues metabolize quercetin, J. Nutr. 136, 39 (2006).
46. K. T. R. Shantha, S. Chawla, S. K. Nachaegari, S. K. Singh, and N. R. Srinivas, Validated HPLC analytical method with programmed wavelength UV detection for simultaneous determination of DRF-4367 and Phenol red in rat in situ intestinal perfusion study. J. Pharm. Biomed. Anal. 38, 173 (2005).
47. H. Lennernas, O. Ahrenstedt, R. Hallgren, L. Knutson, M. Ryde, and L. K. Paalzow, Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9, 1243 (1992).
48. Y. Q. Hu, L. Y. Zheng, C. Q. Qian, and W. H. Yu, Absorption in small intestinal tract of ion drug-Phenolsulfonphthalein. J. Chin. Pharm. Univ. 27, 355 (1996).
49. S. C. Sutton, M. T. Rinaldi, and K. E. Vukovinsky, Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS. PharmSci. 3, 25 (2001).
50. J. Ritesh, D. Sridhar, K. Viral, K. M. Nanda, and K. M. Ashim, Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. Int. J. Pharm. 336, 233 (2007).
51. Z. G. Liao, Q. N. Ping, W. Xiao, and X. L. Liang, The study in situ on rat intestinal absorption of the active components in GuizhiFuling capsule. Chin. J. Natural. Med. 3, 303 (2005).
52. J. Cui, G. X. Zhai, and H. X. Lou, Preparation and characteristics of curcumin microemulsion. Chin. Pharm. J. 24, 1877 (2007).
53. J. Wang, H. T. Song, and X. Zhou, In situ intestinal absorption kinetics of sirolimus in rats. Chin. Pharm. 20, 27 (2009).
54. Y. Pak, R. Patek, and M. Mayersohn, Sensitive and rapid isocratic liquid chromatography method for the quantitation of curcumin in plasma. J. Chromatogr. B. 796, 339 (2003).
55. D. J. Hauss, S. E. Fogal, J. V. Ficorilli, C. A. Price, T. Roy, A. A. Jayaraj, and J. J. Keirns, Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J. Pharm. Sci. 87, 164 (1998).
56. R. J. Sokol, K. E. Johnson, F. M. Karrer, M. R. Narkewicz, D. Smith, and I. Kam, Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 338, 212 (1991).
57. L. Yu, A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, and M. Coffin, Vitamin E-TPGS increases absorption ?ux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16, 1812 (1999).
58. J. M. Dintaman and J. A. Silverman, Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 16, 1550 (1999).
59. M. Shinitzky and M. Inbar, Microviscosity parameters and protein mobility in biological membranes. Biochim.Biophys. Acta 433, 133 (1976).
60. A. Angele and A. Hubert, Membrane fluidity and it's alteration in disease. Biomembrane. 14, 63 (1988).
61. S. Senel, M. J. Kremer, S. Kas, P. W. Wertz, A. A. Hincal, and C. A. Squier, Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials 21, 2067 (2000).
62. K. K. Gupta, S. S. Bharne, K. Rathinasamy, N. R. Naik, and D. Panda, Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS J. 273, 5320 (2006).
63. S. L. Thomas, D. Zhong, W. Zhou, S. Malik, D. Liotta, J. P. Snyder, E. Hamel, and P. Giannakakou, EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1 Cell Cycle. 7, 2409 (2008).
64. G. Bohm, CDNN: CD Spectra Deconvolution Software Version 2.1 Univ. of Halle-Wittenberg, Halle, Germany (1997).